ROGER D. STANWORTH, BMEDSCI, KEVIN S. CHANNER, MD DHEERAJ KAPOOR, MD T. HUGH JONES, MD
OBJECTIVE: There is a high prevalence of hypogonadism in men with type 2 diabetes. This will lead to an increase in assessments of hypogonadism. Statins could potentially decrease testosterone levels by reducing the availability of cholesterol for androgen synthesis. We com- pared testosterone levels and hypogonadal symptoms with statin use in a cross-sectional study of 355 men with type 2 diabetes.
RESEARCH DESIGN AND METHODS: Total testosterone, sex hormone–binding
globulin (SHBG), and estradiol were measured by an enzyme-linked immunosorbent assay. Bioavailable testosterone was measured by the modiﬁed ammonium sulfate precipitation method. Free testosterone was calculated using Vermeulen’s formula. Symptoms of hypogonadism were assessed using the Androgen Deﬁciency in the Aging Male questionnaire.
RESULTS: Statins were associated with lower total testosterone (11.9 vs. 13.4 nmol/l, P 0.006) and a trend toward lower SHBG (29.4 vs. 35.3 nmol/l, P 0.034) compared with no treatment. Bioavailable testosterone, free testosterone, estradiol, and hypogonadal symptoms were not affected. Subanalysis showed that atorvastatin was associated with reduced total testosterone (11.4 vs. 13.4 nmol/l, P 0.006) and a trend toward reduced SHBG (27.6 vs. 35.3 nmol/l,P 0.022) compared with no treatment, and there was an apparent dose-response effect
with the lowest levels of total testosterone seen in men treated with 20 mg atorvastatin (9.6 nmol/l, P 0.017). Simvastatin use was not associated with signiﬁcant reductions in testosterone or SHBG levels.
CONCLUSIONS: Assessing androgen status using total testosterone in men with type 2 diabetes treated with statins, particularly atorvastatin, may potentially lead to diagnostic error. Levels of bioavailable testosterone or free testosterone are recommended for the assessment of hypogonadism in this group if total testosterone levels are borderline.